Harel Insurance Investments & Financial Services Ltd. Sells 21,260 Shares of Pfizer Inc. (NYSE:PFE)

Harel Insurance Investments & Financial Services Ltd. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 28.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,199 shares of the biopharmaceutical company’s stock after selling 21,260 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Pfizer were worth $1,532,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. RB Capital Management LLC raised its stake in Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. raised its stake in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after buying an additional 400 shares in the last quarter. United Bank raised its stake in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after buying an additional 290 shares in the last quarter. Ergoteles LLC grew its holdings in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp grew its holdings in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 1st. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Finally, TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Trading Down 1.8 %

Shares of Pfizer stock opened at $25.86 on Monday. The company’s fifty day simple moving average is $27.28 and its 200-day simple moving average is $28.88. The stock has a market capitalization of $146.43 billion, a PE ratio of 71.83, a P/E/G ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 1-year low of $25.61 and a 1-year high of $41.71. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.14 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.